Acute tubular necrosis is characterized by activation of the alternative pathway of complement.

BACKGROUND Studies in animal models have shown that the alternative pathway of complement is activated in the kidney after ischemia/reperfusion. In addition, mice deficient in complement factor B, a necessary component of the alternative pathway, are protected from ischemic acute renal failure. The purpose of this study was to determine whether alternative pathway activation also occurs during the development of ischemic acute tubular necrosis in the human kidney. METHODS Biopsies were identified from nine patients with morphologically normal kidneys and seven patients with evidence of acute tubular necrosis by light microscopy. Immunofluorescence microscopy was used to quantify and localize the complement activation products C3d and C4d. The results were correlated with available clinical data. RESULTS Similar to mice, small amounts of activated C3d were present along the tubular basement membrane in normal kidneys. However, kidneys from patients with acute tubular necrosis had C3d complement deposition along a significantly greater number of tubules, and many of the tubules were completely circumscribed. In contrast, C4d was not detectable, indicating that complement activation occurred primarily via alternative pathway activation. CONCLUSION Complement activation occurs in human ischemic acute tubular necrosis. As in rodents, complement activation along the tubular basement membrane after ischemia appears to occur principally via the alternative complement pathway. Because of this, an inhibitor of the alternative pathway might limit complement activation and inflammation after ischemia/reperfusion, thereby protecting the kidney from ischemic acute renal failure.

[1]  M. Weiser,et al.  Intestinal reperfusion injury is mediated by IgM and complement. , 1999, Journal of applied physiology.

[2]  S. Richards,et al.  Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. , 2004, The New England journal of medicine.

[3]  Dible Jh,et al.  Acute tubular necrosis. , 1950 .

[4]  K. Abe,et al.  Predominant role for C5b-9 in renal ischemia/reperfusion injury. , 2000, The Journal of clinical investigation.

[5]  V. Vetvicka,et al.  Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle. , 1993, Journal of immunology.

[6]  W. Couser,et al.  Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors? , 2003, Journal of the American Society of Nephrology : JASN.

[7]  J. Thurman,et al.  Lack of a Functional Alternative Complement Pathway Ameliorates Ischemic Acute Renal Failure in Mice 1 , 2003, The Journal of Immunology.

[8]  P. Heeringa,et al.  Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation1 , 2003, Transplantation.

[9]  C. West Complement and Glomerular Disease , 1998 .

[10]  K. Solez,et al.  The Morphology of “Acute Tubular Necrosis” in Man: Analysis of 57 Renal Biopsies and a Comparison with the Glycerol Model , 1979, Medicine.

[11]  W. Buurman,et al.  Reduction of circulating redox-active iron by apotransferrin protects against renal ischemia-reperfusion injury1 , 2004, Transplantation.

[12]  M. Entman,et al.  The inflammatory response in myocardial infarction. , 2002, Cardiovascular research.

[13]  P. Chowdhury,et al.  Role of the complement system in rejection. , 2003, Current opinion in immunology.

[14]  P. Armstrong,et al.  Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) Trial , 2003, Circulation.

[15]  T. Hostetter,et al.  Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. , 1985, The Journal of clinical investigation.

[16]  J. Thurman,et al.  A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. , 2005, Molecular immunology.

[17]  R. Quigg We need to inhibit complement in glomerular proteinuria. , 1999, Kidney international.

[18]  T. Lindsay,et al.  Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. , 1992, Journal of immunology.

[19]  J. Alexander,et al.  Injury in renal ischemia-reperfusion is independent from immunoglobulins and T lymphocytes. , 2002, American journal of physiology. Renal physiology.

[20]  J. Bonventre Mechanisms of ischemic acute renal failure. , 1993, Kidney international.

[21]  A. Romaschin,et al.  Complement activation and white cell sequestration in postischemic skeletal muscle. , 1990, The American journal of physiology.